Form 4: Matinas BioPharma CEO Jerome Jabbour Awarded Stock Options Subject to Shareholder Approval

Matinas BioPharma Holdings CEO Jerome D. Jabbour was granted stock options for 70,100 shares, contingent on shareholder approval of the company's 2025 Equity Incentive Plan.

Summary

• Jerome D. Jabbour, the President and CEO of Matinas BioPharma Holdings, Inc., was granted stock options to purchase 70,100 shares of common stock on April 30, 2025.
• The exercise price of these options is $0.59 per share.
• The options vest subject to stockholder approval of the 2025 Equity Incentive Plan, with 25% vesting on April 30, 2026, and the remaining shares vesting in equal monthly installments over 36 months starting April 30, 2026.
• The options expire on April 30, 2035.
• This transaction was reported on a Form 4 filed with the SEC on May 2, 2025.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting a stable and incentivized management structure. The sentiment is neutral to positive as it indicates alignment of interests between management and shareholders.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Risks

• The vesting of the options is contingent on shareholder approval of the 2025 Equity Incentive Plan; failure to obtain this approval would impact the CEO's compensation.
• The value of the options is dependent on the future performance of Matinas BioPharma's stock.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options and the shareholder vote on the 2025 Equity Incentive Plan.

Industry Context

Granting stock options to executives is a common practice in the biopharmaceutical industry to incentivize performance and align management's interests with those of shareholders. The size and terms of the grant are typical for a company of Matinas BioPharma's size and stage of development.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amarin and Esperion, which are in a similar space, also use stock options to incentivize their executives.
• The vesting schedule and exercise price are generally in line with industry norms, although specific terms can vary based on individual performance and company goals.

Stakeholder Impact

• Shareholders: Potential dilution of ownership if the options are exercised.
• Employees: May be impacted by the overall success of the company, which the CEO is incentivized to drive.
• CEO: Incentivized to increase shareholder value through stock options.

Next Steps

• Shareholder vote on the 2025 Equity Incentive Plan at the annual meeting on June 23, 2025.
• Vesting of the options according to the specified schedule, contingent on plan approval.

Key Dates

Keywords

stock options, Matinas BioPharma, Jerome Jabbour, CEO, equity incentive plan, Form 4, MTNB, vesting